Mabquest Sa

Consejo Superior De Investigaciones Cientificas

Ippox Foundation

Arizona State University

Arizona Board of Regents, a Body Corporate

Centre Hospitalier Universitaire Vaudois

Other

Universitéde Montreal

Sanofi Pasteur Inc.

Institute for Research in Biomedicine

Academisch Zikenhuis Leiden

Giuseppe Pantaleo

Alexandre Harari

Craig Fenwick

James Tartaglia

Karen Kibler

Mariano Esteban

Thierry Calandra

Cornelius Melief

Thierry Roger

Rafick-Pierre Sekaly

Bertram L Jacobs

Elias El Haddad

Antonio Lanzavecchia

Bertram Jacobs

Elias Haddad

Matthieu Perreau

Mario Esteban

The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Modified immunization vectors

This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch ('P2') on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.

Immunological reagents

This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity.

This disclosure relates to binding agents with specificity for HIV and to methods for using the same to treat, prevent and/or ameliorate HIV infection and/or AIDS.

HIV binding agents

This disclosure relates to methods for differentiating between mammals having active and latent Tuberculosis disease, by determining the percentage of polyfunctional CD4+ T-cells expressing TNF-alpha, IFN-gamma, and IL-2, or by determining expression of IL-17.

Methods for differentiating between disease states

Growing community of inventors

Lausanne, Switzerland

Giuseppe Pantaleo